Mitchell R. Smith

Immunology · 2003–2017

A researcher in the Science corpus: 2 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Mitchell R. Smith trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Ravetch

Papers from Mitchell R. Smith's perspective

Ordered by how strongly the researchers Mitchell R. Smith trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. (Blood)
  2. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. (Blood)
  3. Immune inhibitory receptors. (Science)
  4. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. (Journal of Clinical Oncology)
  5. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. (Blood)
  6. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. (Journal of Clinical Oncology)
  7. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. (New England Journal of Medicine)
  8. Current concepts in the diagnosis and management of cytokine release syndrome. (Blood)
  9. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. (The Lancet Oncology)
  10. CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells (Journal of Immunology)

Their papers